Cancer is a complex and multifaceted disease characterized by the uncontrolled growth and spread of abnormal cells within the body.

Understanding the nature of cancer as a systemic issue rather than merely a localized one is crucial for effective treatment.

These cancer cells can form tumors and possess the ability to invade surrounding tissues and metastasize to distant organs. 

The mechanisms behind cancer development are varied and can include genetic predispositions, environmental exposures, and lifestyle factors.

                                                                                                                                                                                    Dr. Donato Perez Garcia, with over 42 years of experience in treating chronic degenerative diseases and certain types of cancer, emphasizes the systemic nature of cancer. According to him, cancer is not simply a tumor; it is a disruption of normal biological functions that necessitates a comprehensive approach to treatment.

Initial treatment strategies often involve systemic drug therapies administered intravenously, designed to nourish the body, reduce inflammation, and stimulate the immune response. Dr. Garcia advocates for targeting the tumor's interior cells, recognizing that traditional approaches may only address symptoms without providing long-term solutions. Surgical interventions, while sometimes necessary, may not always be viable for long-term outcomes, making systemic treatment an essential part of a holistic approach to cancer care.

Survival rates can vary significantly based on the type of cancer, its stage at diagnosis, and the age of the patient. Dr. Garcia's IPT/IPTLD therapy is presented as a promising option for patients seeking effective and prolonged responses to treatment. The focus on systemic rather than symptomatic approaches underscores the need for innovative therapies that address the root causes of cancer.

In conclusion, cancer represents a significant challenge in modern medicine, requiring a nuanced understanding and a tailored approach to treatment. Dr. Garcia's insights highlight the importance of systemic therapies that not only target tumors but also restore balance to the body's intricate biological systems. Through careful consideration of individual patient needs and the underlying mechanisms of cancer, it is possible to improve survival outcomes and enhance the quality of life for those affected by this formidable disease.

Here are a few scientific references:

1- Insulin for Everything. TIME magazine April 10, 1944

2- Ayre SG, Perez Garcia y Bellon D, Perez Garcia Jr D.  Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas.  Eur J Cancer. 26:1261-2, 1990

3- Breast Carcinoma Treated by a Regimen of Low-Dose Chemotherapy and Insulin: Report of Four Cases and Pharmacokinetic Considerations. Steven G. Ayre, Donato Perez Garcia y Bellon, and Donato Perez Garcia, Jr. Forty-second Annual Symposium on Fundamental Cancer Research. THE UIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.

4- IPT Text Book. Sachihiko Okuno,M.D. Osaka,Japan.

For MORE SCIENTIFIC REFERENCES GO TO:

https://iptld.blogspot.com/2025/05/scientific-publications-that-support.html

My 20-Year Remission Story: A Journey of Hope.In Memory of Annie B.

In Memory: Honoring the indomitable spirit of a remarkable woman, Annie, whose journey through the shadows of illness illuminated a path of hope and resilience is both a privilege and a profound testament to the power of determination. 

Diagnosed with cancer in 2001, Annie faced a future that many would find bleak. 

With an oncologist’s grim prognosis echoing in her ears, she stood at a crossroads where despair and hope collided. Instead of succumbing to fear, she made a pivotal decision to undergo insulin potentiation therapy under my care, a choice that required immense courage and an unwavering belief in herself. The road was fraught with challenges, but Annie’s resolve was unshakeable. As she navigated the complexities of her treatment, she embodied the essence of strength, perseverance, and trust. The therapy not only transformed her health but also defied the expectations set forth by the medical community. Against all odds, she emerged victorious, a shining example of success and a beacon of hope for others facing similar battles. Her recovery was not merely a personal triumph; it was a clarion call to others that survival was possible, even when the odds seemed insurmountable. Annie’s journey did not end with her own recovery. Inspired by her experience and fueled by an unwavering desire to help others, she founded Best Answer for Cancer. This foundation became a sanctuary for those seeking guidance, support, and innovative treatments in their fight against cancer. By bringing together like-minded medical professionals and patients, Annie fostered a community grounded in hope, knowledge, and shared experience. Through her efforts, she opened doors to alternative treatments and empowered individuals to take charge of their health journeys. As someone who had the honor of being part of her recovery, I am continually inspired by Annie’s legacy. Her story is a powerful reminder that the human spirit, when faced with adversity, can rise to unimaginable heights. Annie was not just a patient; she was a catalyst for change, a pioneer in holistic healing, and a true advocate for women and patients battling cancer. Her unwavering commitment to making the world a better place and her relentless pursuit of successful medical interventions will forever resonate in the hearts of those she touched.

Her testimony:

"Dr. Donato, quite simply, saved my life! I will always be grateful to him, he will always hold a special place in my heart, and I will never be able to repay him. I was diagnosed with advanced-stage breast cancer on Friday the 13th of July, 2001, after a biopsy of a swollen lymph node. Because they found it in my lymphatic system, I was automatically at least stage II, with metastatic breast cancer as my diagnosis. The doctor immediately booked me for a double mastectomy, chemo and radiation, starting the following Tuesday. Because I have a dysfunctional immune syndrome as well as several other immune-related diseases, I knew that I had to be careful about what I did to, and put into, my body. After extensive research that weekend, I came to the conclusion that traditional surgery, chemo and radiation would kill me. I decided to try alternative treatments. I did research and found IPT. I was so excited when I read about this gentle yet effective therapy: kind to the patient, tough on the cancer. It was also important to me that it had been used successfully against cancer for decades. The doctors found, during further tests, that I had lesions in my brain and my lungs. When I told my doctors about my decision to do IPT instead of conventional, they predicted that I would be dead within six months.

I searched the existing database on GETIPT.com for a doctor near me in Austin, Texas. However, because the website and database were a volunteer effort by one overworked researcher, they were not up-to-date; the doctors listed near me were no longer in practice. Also, because the therapy was still considered “experimental” (even after 70 years in existence and 40 years of use as a successful cancer therapy), my insurance would not pay for any of the treatments. With the overhead of U.S. medical practices, the treatments were more than I could afford. I decided to call the grandson of the inventor and the most experienced IPT practitioner, Dr. Donato Perez Garcia III, in Tijuana, Mexico. I was used to the lead time for appointments in the U.S. being several weeks, so he surprised me when he informed me that he could evaluate my case as soon as I could get there. When I asked how long after that I would have to wait for treatment, should he decide to accept me as a patient, he said he could do a treatment the same day as evaluation, if he thought he could help me! The added value was that the overhead is much lower in Mexico, so I could actually imagine affording the treatments. I made my appointment for later that week. I made both airline and hotel reservations, and I gathered my medical records. The email that Dr. Donato had sent me gave me explicit instructions and directions, so I felt fairly comfortable. I had heard stories about the border cities in Mexico, so I was somewhat concerned, but, again, Dr. Donato put me at ease. Little did I know that his office was overlooking a golf course and the buildings known as the “Twin Towers of Tijuana”. When I got to Dr. Donato’s office, I was pleasantly surprised to find an office that looked just like any other doctor’s office. The receptionist spoke fluid English, and I was soon shown into Dr. Donato’s office. He spoke with me for a long time, examined my records, and then said he thought he could help me. He asked if I would like to have my first treatment. Having hoped for that eventuality, I had fasted starting at midnight the night before: I was ready!

The treatments are easy and last about 2 hours. I am very comfortable; I usually read a book during the first part of the treatment. Dr. Donato is very available before, during, and after the treatment. He answers all questions and concerns. The IPT treatments are very gentle. I never lost my hair, and I never got sick. The treatments made the cancer a non-event! I actually considered my treatment trips a mini-vacation! How many times have you heard a cancer patient say that?"

IN MEMORY (Annie Brandt,1955 - 2021)

I have cancer and a very elevated tumor marker. What does this mean and what can I do? Don't ditch your hope!

Hope is intrinsically linked to our emotional and spiritual well-being. When we abandon our soul and heart, we essentially forsake our connection to our hopes and dreams. Without these vital components, hope fades, leaving a void that can be difficult to recover from.

I am deeply sorry that you are facing this difficult and distressing situation. Receiving a cancer diagnosis and having an elevated tumor marker can be overwhelming. It is completely natural to feel a mix of emotions, from fear to confusion. However, it is essential that you seek to fully understand what an elevated tumor marker means and how you can best address your situation.

A tumor marker is essentially a substance produced in the body, often a protein, and whose presence can be detected in blood, urine, or other bodily fluids. Its primary function is to act as an indicator of cellular activity in the body, which includes not only cancer cells but also the body's responses to concomitant conditions. In optimal health, levels of these markers are usually low or undetectable.

It is important to clarify that an elevated tumor marker does not always mean uncontrolled cancer. Multiple factors can influence the elevation of these markers. In most cases, for example, concurrent (happening in your body at the same time of your cancer): infections, inflammation, or even certain benign conditions can cause an increase in the levels of these markers. Therefore, it's vital not to panic when faced with an elevated result. The key is to analyze this result in the context of other blood tests and, above all, in relation to your overall health.

In my experience, I've had patients whose tumor markers remained elevated but who showed significant improvements when the normal components of blood return to normal ranges, eventually leading to the normalization of those markers.

The interpretation of tumor marker results should be done in conjunction with other tests and the patient's clinical context. It's essential that you stay in touch with me. My experience allows me to provide you with a comprehensive and personalized approach, providing regular follow-up to monitor the evolution of these markers and other health parameters. Open communication with me is key; don't hesitate to share your concerns, questions, or any symptoms you may be experiencing. This will allow me to tailor your treatment and offer you the support you need. I'm here to help you understand what these results mean for you and what your next step should be.

Additionally, it's crucial to take care of yourself in every way possible, as every element of your lifestyle can influence your well-being. Nutrition plays a vital role in this process; choosing a balanced, nutrient-dense diet can help your body fight the disease. Including anti-inflammatory foods, such as fresh fruits and vegetables, whole grains, healthy fats, and lean proteins, can be beneficial but sometimes multiple mixes/combinations in one dish, they can produce alterations in liver tests. Likewise, staying well hydrated and considering reducing your consumption of sugars and processed foods can help your body function more efficiently.

Moderate exercise has also been shown to have positive effects on health during cancer treatment. Activities such as walking, yoga, or swimming can help improve your mood and overall well-being. Practicing stress-reduction techniques, such as meditation, deep breathing, or even art therapy, can be a powerful tool for managing the anxiety and stress that often accompany a cancer diagnosis.

If you decided to be treated with my treatment protocol, it's a program I learned more than 40 years ago with my father. It's an effective alternative treatment, and this targeted therapy eliminates cancer cells and promotes tissue repair. What I do isn't what your oncologist does, and they can't offer it to you because they aren't trained in my technique. Perhaps several doctors who came to my clinic in the past to take the basic course continue to do so, but they've fallen behind with the updates. There are also many doctors who read the description of the procedure online and claim to do it. So when you're under my care, rest assured that today there is no other doctor with my experience. What I do is based on the knowledge I learned from my father over more than 40 years, which over time has given me more experience to make the best decisions to achieve the best results. I always continue learning, even when the decisions I make don't produce the expected results. Finally, I can tell you that I have several patients—yes, several—many who have regained their health, beaten cancer, and survived for more than 32 years. I've received calls from patients or their families who were treated by my father in the 1960s. If I were to ask how many patients treated with traditional oncology survive beyond five years, it would be few.

Additionally, it's important to remember that each person is unique, and what works for one person may not be applicable to another. Emotional resilience and psychological support are equally important.

In conclusion, facing a cancer diagnosis and interpreting tumor markers is a complex process that requires a multifaceted approach. Maintain open communication with me, don't neglect or rely on scheduling your appointments for your treatment with me and prioritize your physical and emotional health. Hope and determination are powerful allies in this fight. If you have any further questions or need additional support, don't hesitate to ask. I'm here to offer you the information and support you need throughout this process.

Scientific Publications that support the use of insulin as a biologic response modifier: off-label use of the drug. Insulin Potentiation Therapy or IPT, IPTLD.

1)Poster Presentation at the Third Annual Comprehensive Cancer Management Conference, Washington, DC June 2000

Primary Breast Conserving Treatment for Breast Cancer Using Biologic Response Modification with Insulin in Combination with Non-Toxic Low-Dose Chemotherapy. Steven G. Ayre, M.D.

2)Insulin Shows Promise

Oncology News, 1991, 17(4):1,7

3) Ayre SG, Perez Garcia y Bellon D, Perez Garcia Jr D.  Neoadjuvant low-dose chemotherapy with insulin in breast carcinomas.  Eur J Cancer. 26:1261-2, 1990

4) Ayre SG, Perez Garcia Y Bellon D, Perez Garcia Jr D.  Insulin potentiation therapy:  a new concept in the management of chronic degenerative disease.  Medical Hypotheses 20:199-210, 1986

5) Lippman ME, Dickson RB, Kasid A, et al.  Autocrine and paracrine growth regulation of human breast cancer.  J Steroid Biochem 24:147-154, 1986

6) Hilf R.  The actions of insulin as a hormonal factor in breast cancer.  In:  Pike MC, Siiteri PK, Welsch CW, eds.  Hormones and Breast Cancer, Cold Spring Harbor Laboratory, 1981, 317-337.

7) Cullen JK, Yee D, Sly WS, et al.  Insulin-like growth factor receptor expression and function in human breast cancer.  Cancer Res 50:48-53, 1990

8) Holdaway IM, Freisen HG.  Hormone binding by human mammary carcinoma.  Cancer Res 37:1946-1952, 1977

9) Papa V,  Pezzino V, Constantino A, et al.  Elevated insulin receptor content in human breast cancer.  J Clin Invest 86:1503-1510, 1990

10) Sporn MB, Todaro GJ.  Autocrine secretion and malignant transformation of cells.  N Engl J Med 308:487-490, 1980

11) Jaques G, Rotsch M, Wegmann C, et al.  Production of immunoreactive insulin-like growth factor 1 and response to exogenous IGF-1 in small cell lung cancer cell lines.  Exp Cell Res 176:336-343, 1988

12) Nakanishi Y, Mulshine JL, Kasprzyk PG, et al.  Insulin-like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.  J Clin Invest 82:354-359, 1988

13) Lee PDK, Rosenfeld RG, Hintz RL, Smith SD.  Characterization of insulin, insulin-like growth factors I and II, and growth hormone receptors on human leukemic lymphoblasts.  J Clin Endocr Metab 62:28-35, 1986

14) Colman PG, Harrison LC.  Structure of insulin/insulin-like growth factor-1 receptors on the insulinoma cell, RIN-m5F.  Biochem Biophys Res Commun 124:657-662, 1984

15) Zapf J, Froesch ER.  Insulin-like growth factors/somatomedins:  structure, secretion, biological actions and physiological role.  Hormone Res 24:121-130, 1986

16) Papa V, Constance CR, Brunetti A, et al.  Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinomas.  Cancer Res 50:7857-7862, 1990

17) Stewart AJ, Johnson MD, May REB, Westley RB.  Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.  J Biol Chem 265:21172-21178, 1990

18) Eppenberger U.  New aspects in the molecular growth regulation of mammary tumors.  In:  Eppenberger U, Goldhirsch A, eds.  Recent Results in Cancer Research, Vol. 113:  Endocrine Therapy and Growth Regulation of Breast Cancer.  Berlin-Heidelberg, 1989, 1-3

19) DeLeon DD, Bakker B, WIlson RL, et al.  Demonstration of insulin-like growth factor (IGF-I and IGF-II) receptors and binding protein in human breast cancer cell lines.  Biochem Biophys Res Commun 152:398-405, 1988

20) Karey KP, Sirbasku DA.  Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17B-estradiol.  Cancer Res 48:4083-4092, 1988

21) King GL, Kahn CR, Rechler MM, Nissley SP.  Direct demonstration for separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulin-like growth factor) using antibodies to the insulin receptor.  J Clin Invest 66:130-140, 1980

22) Jacobs S, Cook S, Svoboda M, Van Wyk JJ.  Interaction of the monoclonal antibodies alpha-IR-1 and alpha-IR3 with insulin and somatomedin-C receptors.  Endocrinol 118:223-226, 1986

23) Goustin AS, Leof EB, Shipley GD, Moses HL.  Growth factors and cancer.  Cancer Res 46:1015-1029, 1986

24) Unterburger P, Sinop A, Noder w, et al.  Diabetes  mellitus  and  breast  cancer:  a retrospective follow-up study.  Onkologie 13:17-20, 1990

25) Yee D, Palk S, Lebovic GS, et al. Analysis of insulin-like growth-factor I gene expression: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517, 1990

26) Hilf R.  Primary and permissive actions of insulin in breast cancer.  In:  Leung BS, ed.  Hormonal regulation of mammary tumors.  Montreal, Eden Press, 1982, Vol. 2, 123-137

27) Alabaster O, Vonderhaar BK, Shafie SM.  Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells.  Eur J Cancer Clin Oncol 17:1223-1228, 1981

28) Oster JB, Creasey WA.  Enhancement of cellular uptake of ellipticine by insulin preincubation.  Eur J Cancer Clin Oncol 17:1097-1103, 1981

29) Schilsky RL, Bailey BD, Chabner BA.  Characteristics of membrane transport of methotrexate by cultured human breast cancer cells.  Biochem Pharmacol 30:1537-1542, 1981

30) Shinitzky M, Henkart P.  Fluidity of cell membranes – current concepts and trends.  Int Rev Cytol 60:121-147, 1971

31) Jeffcoat R.  The biosynthesis of unsaturated fatty acids and its control in mammalian liver.  Essays Biochem 15:1-36, 1979

32) Gasparro FP, Knobler RM, Yemul SS, Bisaccia E, Edelson RL.  Receptor mediated photo-cytotoxicity:  synthesis of a photoactivatable psoralen derivative conjugated to insulin.  Biochem Biophys Res Comm 141:502-209, 1986

33) Poznansky MJ, Singh R, Singh B.  Insulin:  carrier potential for enzyme and drug therapy.  Science 223:1304-1306, 1984

34) Ayre SG.  New approaches to the delivery of drugs to the brain.  Med Hypotheses 29:283-291, 1989

35) Gross GE, Boldt DH, Osborne CK.  Perturbation by insulin of human breast cancer cell kinetics.  Cancer Res 44:3570-3575, 1984

36) Paridaens R, Klijn JGM, Julien JP, et al.  Chemotherapy with estrogenic recruitment in breast cancer:  experimental background and clinical studies conducted by the EORTC breast cancer cooperative group.  Eur J Cancer Clin Oncol 22:728, 1986

37) Van der Burg B, de Laat SW, van Zoelen EJJ.  Mitogenic stimulation of human breast cancer cells in a growth-factor defined medium:  synergistic action of insulin and estrogens.  In:  Brescani F, King RGB, Lippman ME, Raynaud JP, eds.  Progress in Cancer Research and Therapy, vol. 35:  Hormones and Cancer 3.  New York, Raven Press, Ltd.  1988, 231-233.

38) Goldfine ID, Purello F, Vigneri R, and Clawson GA.  Direct regulation of nuclear functions by insulin:  relationship to mRNA metabolism.  In:  Czech MP, ed. Molecular Basic of Insulin Action.  New York, Plenum Press, 1985, 329-345.

39)Blood Brain Barrier Passage of Azidothyumidine in Rats: Effects of Insulin

Steven G. Ayre (1), Brian Skaletski (2) and Aron D. Mosnaim( 2). 

Research Communications in Chemical Pathology and Pharmacology JANUARY 1989 VOL.63, NO. 1. Departments of Family Medicine and Pharmacology and Molecular Biology , University of Health Sciences/The Chicago Medical School, North Chicago, IL 60064.

40)New Approaches to Delivery of Drugs to the Brain. S.G. Ayre. Medical Hypotheses 29:283-291, 1989

41)Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. S.G. Ayre, M.D., D. P. Garcia Bellon, M.D., D. P. Garcia, Jr., M.D. Medical hypotheses 55.4 (2000): 330-334.

42)Low dose chemotherapy in combination with insulin for the treatment of metastatic tumors: C. Damyanov, M. Radoslavova, V. Gavrilov, D. Stoeva. Medical Center of Integrative Medicine, Sofia, Bulgaria. Journal of BUON 14: 711-15, 2009.

43)Insulin Potentiation Therapy in the treatment of malignant neoplastic diseases: a three year study. Damyanov C, Gherasimova DM, Avramov LA, Masley IK (2012). J Cancer Sci Ther 4: 088-091. doi:10.4172/1948-5956.1000117

44)Low-Dose Chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer. Damyanov, Christo, et al. ISRN urology 2012 (2012).

45)Metabolic Modification by Insulin Enhances Methotrexate Cytotoxicity in MCF-7 Human Breast Cells. Alabaster, O. Vonderhaar, B. and Shafie, S. Eur J Cancer Clin Oncol. Vol 17, No. 11, pp 1223-1228. 1961. 

46)Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, Bosaeus I. Clin Cancer Res. 2007 May 1;13(9):2699 706.

47)Long-Term Effect of Diabetes and Its Treatment on Cognitive Function. Jacobson, Alan, et.al. N Engl J Med 2007; 356:1842-52.

48)Preclinical safety and antitumor efficacy of insulin combined with irradiation. Bénédicte F. Jordan, Nelson Beghein, Nathalie Crokart, Christine Baudelet, Vincent Gregoire, Bernard Gallez. Radiotherapy and Oncology 81 (2006) 112–117.

49)Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Lasalvio-Prisco, Eduardo, et.al. Cancer Chemother Pharmacol (2004) 53: 220–224.

50)The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells. Zhonghua Yi Xue Za Zhi. 2003 Feb 10;83(3):195-7. 

51)Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells. Zou K, Ju JH, Xie H. Acta Pharmacol Sin. 2007 May; 28(5):721-30. 

52)A pilot study of Auron Misheil Therapy (AMT) in patients with advanced cervical cancer: tumor response and its correlation with clinical benefit response, and preliminary quality of life data.” Scheele, Jürgen, et al. Oncology reports 22.4 (2009): 877-883.

53)Insulin in endometrial carcinoma chemotherapy: A beneficial addition and not a problem. Sha, Huilan, et al. Journal of Huazhong University of Science and Technology [Medical Sciences] 30 (2010): 631-637.

54) Insulin for Everything. TIME magazine April 10, 1944

55)Long-Term Outcomes of the Treatment of Unresectable (Stage III - IV)Ductal Pancreatic Adenocarcinoma Using Metabolically Supported Chemotherapy (MSCT): A Retrospective Study

Mehmet Salih Iyikesici1, Ayshe Slocum2*, Engin Turkmen3, Ovunc Akdemir4, Abdul Kadir Slocum5, Turgut Ipek6, Erhun Eyuboglu6, Ferhan Bulent Berkarda7

56)Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. Mehmet Salih İyikesici, Abdul Kadir Slocum, Ayshe Slocum, Ferhan Bulent Berkarda, Miriam Kalamian, andThomas N Seyfried. Cureus. 2017 Jul; 9(7): e1445.Published online 2017 Jul 7. doi:  10.7759/cureus.1445. PMCID: PMC5589510. Monitoring Editor: Alexander Muacevic and John R Adler

57)Integrative Oncology at the Clinicist's Look. Chronology for the Creation and Development of the IPT & BMP Method for Treatment of Oncological Diseases. It is uploaded on the following link: http://www.clinicsinoncology.com/pdfs_folder/cio-v4-id1671.pdf . 

58)The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells

Published Feb 28, 2021 · S. Krajnak, Amelie Loewe, M. Battista+5 more. https://ar.iiarjournals.org/content/anticanres/41/3/1243.full.pdf

59)Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality

Published Aug 31, 2019 · P. Ramteke, Ankita Deb, Varsha Shepal+1 more .https://mdpi-res.com/d_attachment/cancers/cancers-11-01402/article_deploy/cancers-11-01402-v2.pdf?version=1568975785

60)Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2

Published Nov 11, 2019 · Siddarth Agrawal, M. Woźniak, M. Łuc+8 more. https://www.nature.com/articles/s41598-019-53145-x

61)Palliative treatment efficacy of glucose inhibition combined with chemotherapy for non-small cell lung cancer with widespread bone and brain metastases: A case report.

Published Nov 30, 2017 · Yongping Liu, Ya-ping Zhang, X. Mao+5 more. https://www.spandidos-publications.com/10.3892/br.2017.1008/download

62)Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme

Published Jan 18, 2014 · C. Champ, J. Palmer, J. Volek+6 more. https://link.springer.com/article/10.1007/s11060-014-1362-0